Bio B2B 〉 Selective Search Results
Your Selection Setting ：Global；
Selective Search Results :
Pipeline & Platform 41 record(s)；
Taigexyn® (Nemonoxacin) is a novel broad spectrum antibiotic for treatment of bacterial infections. It belongs to a new class of antibiotics known as non-fluorinated quinolone. Taigexyn® was discovered by screening against antibiotic-resistant bacteria and thus has intrinsic activity against the resistant infection which is an increasingly severe problem worldwide.Launched in Taiwan in Dec
Physio-Chemical LaboratoryChemistry faculty of RRL conducts wide range of tests to evaluate the Physical-chemical properties of pure and formulated Agrochemicals in compliance with EEC, OECD, OPPTS and SANCO guidelines.We follow internationally accepted methods like FAO, WHO, AOAC and CIPAC with strict compliance to OECD principles of Good Laboratory Practices.The areas of expertise include:5
FB825 is a humanized monoclonal antibody that binds to the CεmX domain, leading to death of the membrane IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC) in a dosing-dependent manner. FB825 can stand alone as a monotherapy or in combination with Xolair for the treatment of allergic asthma and IgE-mediated diseases.
Core Technology: Pegylation PlatformIn the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. PharmaEssentia's pegylation technology platform is designed to increase the protein drug's efficacy by prolonging its circulation in
ON101- New drug for diabetic foot ulcer healing
When a wound heals, it usually has three phases, the inflammatory phase, proliferative phase, and remodeling phase. The diabetes patients usually have multiple dysfunctional factors such as growth factors, cytokines, and collagen synthesis and these factors are crucial to wound healing. Furthermore, these patients often develop vascular stenosis or obstruction. As a result, blood supply to the wound
Small Molecule Drugs
ScinoPharm possesses a full range of chemistry capabilities and has extensive experience in synthesizing complex molecules. Depending on individual requirements, we develop new synthetic routes, or scale up and optimize processes based on the customer's technology. Our synthesis studies include structured Design of Experiment. (DoE) methods used to identify optimal conditions, factors that most
Synthetic lethality (SL) is a concept in which cell death is induced by the combination of two non-lethal mutations, while mutation alone is not sufficient to affect cell survival. Recently, SL has been proposed as a novel anticancer strategy that is promising to be highly selective. If a cancer-specific mutation combined with a drug-induced mutation have SL interactions, it will selectively
Stabilized Injectable Formulation - SIF
The SIF drug delivery system consists of biodegradable materials dissolved in biocompatible solvents and a bioactive agent that is modified to achieve optimal formulation stability and release profile. The enhanced stability allows the formulation to be pre-filled into a ready-to-use syringe with a suitable storage shelf-life. The fill-finished product can be conveniently administered to patients via
EG12014 Trastuzumab Biosimilar
Eirgenix aims to commercialize the first biosimilar product manufactured in Taiwan for the global market.Indication: HER2 Breast CancerExpected Product Launch: 2020Status: Phase 1 completed, BE established between EG12014 / EU & US HerceptinAdvantages of EG12014- The development of EG12014 follows EMA/FDA published guidance and past experience- EirGenix clinical study set up is considered an asset
IndicationNon-alcoholic steatohepatitis (NASH)Advantages Over Current ProductNo standard treatment availableFirst-in-classFor NASH and ASH bothGreat safety profilePotential MarketThe estimated global market for NASH: 35-40 B per yearCompetitive EdgeMultiple mechanisms of actionDirect action on liverGreat safety profile, US Phase IIApply orphan drug for acute fatty liver in pregnancyStatusUSFDA and
Patented CMx® Platform
Circulating Tumor Cells as Biomarker for Early Cancer Detection. Saving Life, It's in Our Blood.The CMx® Platform uses a biomimetic, lipid-bilayer coated microﬂuidic chip to capture these rare cells in peripheral blood. For colonrectal cancer, the test can be useful in cases of non-compliance with recommended colonoscopies or messy stool tests, and as a supplemental screening.
The laser beams are dynamically focused on the surface of microarray slide based on the auto-focusing function using the focus error signal (FES). The auto-focusing of the laser beam is controlled using the focusing voice coil motor (VCM) to adjust the vertical distance between the objective lens and the surface of the sample slide on the basis of the FES (= (A+C)−(B+D), where A, B, C, and D
Advanced technology in material science
To strengthen the company's R&D capability, BenQ Materials aggressively recruits talents in the field of chemical engineering, physics, chemical materials, polymers, biology, and medicine. Teams operate in a culture characterized by a spirit cooperation, mutual learning and sharing, and a desire to probe fundamental causes. With this R&D strategy as a base, we aim to pioneers and leaders
Locking Plate System
Aplus, found in Taiwan in 2009, devotes itself to the research and development of orthopedic medical products. The Aplus team is known for its focus on, and innovation in, the orthopedic trauma field and the construction of a partnership among industry, academia, research circles, and the medical community.
JHL1266 Denosumab Biosimilar
JHL1266 is a proposed biosimilar to denosumab, which is a monoclonal antibody used for treatment of a range of osteoporosis.
IndicationNon-alcoholic steatohepatitis (NASH)Advantages Over Current ProductOptimized New Chemical EntityFirst-in-classFor NASH and ASH bothPotential MarketThe estimated global market for NASH: 35-40 B per yearCompetitive EdgeMultiple mechanisms of actionDirect action on liverOptimal potencyGreat safety profileStatusPre-clinicalSNP-630 and/or its active metabolites: some human experiencePlan to apply
There are 415 million diabetes patients in the world by 2015 and 10-15% of them have DFU which may lead to amputation or even death.ON101 is the first botanic drug for diabetic foot ulcer (DFU). Target Chronic DFU with Grade 1 or 2 per Wagner Ulcer Classification SystemFulfill the Global Unmet Medical Need in DFUClinical Status: Phase III Interim Analysis (2016)In compliance to US FDA &ldquo
● Ergonomically integrating ultrasonic probe, control switches and HD display in one device● Clever gel delivery with interrupting scan● Ideal companion for US-guide invasive procedure● Compatible with all ultrasound systems● Adjustable grip for easy scan of different body parts
OB318- New drug for anti-liver cancer
Liver is the largest and the most complex organ in human body. Liver cancer is more prevalent among Oriental people; it is a Top 3 cancer in Taiwan and China. Doctors’ treatment options, e.g. surgery, chemotherapy, radiotherapy, biological preparations, or combination therapy, etc., usually depend on disease staging, liver function, patient’s age, and physical condition. Compared to other
CX-5461: RNA Polymerase I (Pol I) Inhibitor Program
The p53 protein normally functions as a tumor suppressor by causing cancer cells to self-destruct. Activating p53 to kill cancer cells is a well validated anticancer strategy and many approaches are being employed to exploit this pathway. By targeting RNA Polymerase I (Pol I) to activate p53 in cancer cells but not normal cells, through the nucleolar stress pathway, Senhwa's first-in-class
New Chemical Entities - NCE
The up regulation of the proteolytic enzyme MMP-12 is implicated in many diseases, such as idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), acute lung injury (ALI), Alport syndrome (rare genetic kidney disease), atherosclerosis, ischemic retinopathy, wound healing, multiple sclerosis, cystic fibrosis, osteoarthritis, rheumatoid arthritis, allergic rhinitis, inflammatory bowel
CellMax SMSEQ® PlatformAnalytical specificity of ≥99.999%CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify
JHL1152 Ipilimumab Biosimilar
JHL1152 is a proposed biosimilar to ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.
SB01 is a new drug originated in Taiwan, from discovery, research and development, preclinical ADME, API and finished product manufactured to the USFDA IND. SB01 is an injectable anti-cancer NCE with multiple anti-tumor MOATreatement of cholangiocarcinoma has FDA Orphan Drug Designation clearancePhase I results show a favorable safety profilePhase II clinical trial of SB01 has
IndicationAnalgesic and antipyreticAdvantages Over Current ProductHepatotoxicity-freeTo address the important and urgent unmet medical needsA patented formulation with great safety marginPotential MarketAcetaminophen sales are 1.3 billion USD a year (US only)Competitive EdgeCurrently, no hepatotoxicity-free acetaminophen on the marketGreat impact on the market share of pain controllers, especially
MS-20 is a mixture of soy fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics human intestinal environment.The manufacturing and R&D procedures of Chemo Young follow the international regulations.MS-20 was approved as new drug by TFDA in 2011.MS-20 acts as an immunemodulator and probiotics to improve immunity and
CX-4945: CK2 Inhibitor Program
CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair. The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents. Inhibitors of DNA repair pathways have been shown to increase the efficacy of DNA-damaging chemotherapeutic drugs when these are used in combination
Friendly GUI interface for reading and displaying 16 bit TIFF image files.GenePix Array List (GAL) file or MSK file. Optical image multi-block circular array of fluorescent spots. Tiff image generated by the automatic selection of slide bits on the fluorescence spots.Adjustable image brightness and contrast.Display histogram distribution of fluorescent reaction of wavelengths 532nm and/or
JHL1255 Ustekinumab Biosimilar
JHL1255 is a proposed biosimilar to ustekinumab, a human monoclonal antibody that is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
PHN033 (Diabetic Nephropathy treatment)
Advantages of the productSelection of native plants for control the medicinal origin and qualityLong-term human experience show no drug- related toxicityDecreases serum AGEs and urine albumin concentration, The new drug with new mechanism of action .Characteristic fingerprint to ensure superior quality controlWell-defined specifications to prove the consistency of quality among batches
AmCAD-UO is an innovative solution to assist physicians evaluating the risk of Obstructive Sleep Apnea (OSA) syndrome.The solution consists of a positioning system and a computer-assisted detection software device.The evaluation process is performed on awake patients and takes no more than 10 minutes to get the results.The entire process is objective, accurate, cost-effective and safe and is expected
ScinoPharm provides comprehensive peptide synthesis technologies with full analytical and regulatory support. With rich knowledge and expertise in peptide synthesis and proprietary platform technologies, ScinoPharm can design and develop higher yield processes for larger-scale peptides that are scalable and more cost effective, ensuring faster time-to-market.Peptide Synthesis CapabilitiesSynthesis
IndicationHepatotoxicity-free AnalgesicAdvantages Over Current ProductHepatotoxicity-free Acetaminophen prescription ComboA new combination with great safety marginPotential MarketAcetaminophen prescription Combo sales are 2.7 billion USD a year (US only)Competitive EdgeNo hepatotoxicity-free acetaminophen prescription Combo on the marketAcetaminophen prescription combos were requested by USFDA
JHL1178 Ramucirumab Biosimilar
JHL1178 is a proposed biosimilar to ramucirumab, a human IgG1 that binds to VEGFR2, which in turn blocks the natural ligands secreted by tumors, therefore can inhibit tumor angiogenesis.
TRIA11 is a biosimilar indicated for osteoporosis. The current global sales of the original product reaches to $1.7 billion. An injection pen is also developed to enhance the convenience of use. TRIA11 is planned to launch in EU first, and TSH Biopharm has consulted EMA for the development plan. TRIA11 is expected to move into clinical stage by the end of 2019.
PHN013 (Orphan drug;ITP)
Advantages of the productPG2 Injection is originally extracted, isolated and purified from the "superior" Tranditional Chinese Medicine (TCM) and it has been confirmed with high safety because of the over 600 cases clinical practice.PG2 Injection meets the current trend of new drug developmentPG2 Injection synchronously modulates the WBCs, RBCs and Platelets.PG2 Injection has been granted
AmCAD-CA, specially designed for microscopy cytology is the only commercially available software specifically designed for cytopathology analysis. AmCAD-CA features visualization and quantification of clinical characteristics, such as nucleus size, circularity, polarity and elongation, nuclear-cytoplasm ratio, inclusion bodies, etc, for cytology microscopic images, aiding professionals in biological
Advantages of the productAdvantages include replacing complicated surgeries such as harvesting cells from bone marrow .Reducing recovery period for dental implants and alveolar bone reconstruction, and improving patient quality of life.Low immune riskNotable achievementsAwarded Advanced Medical Development and Rapid Commercialization program grant support by the Industrial Development Bureau of the
AdvantageAdvantages include replacing complicated surgical procedures, such as harvesting cells from cartilage allografting, or bone marrow .Promoting the repair and functional regeneration of cartilage affected by degenerative OA, and improving patients' quality of life.Low immune risk